Boehringer May Sell U.S. Generics Unit

According to Bloomberg sources, Boehringer Ingelheim is considering the sale of its U.S. Roxane Labs business, valued at as much as $2.4 billion.
Jan. 15, 2015

According to Bloomberg sources, Boehringer Ingelheim is considering the sale of its U.S. Roxane Labs business, valued at as much as $2.4 billion.

Sources say the German drugmaker is working with Morgan Stanley on the possible sale of Ohio-based Roxane Labs, which is Boehringer's generic pharmaceutical business.

A Boehringer spokewoman would only confirm that the company is "exploring strategic options" when contacted by Bloomberg.

Read the Bloomberg release

Sign up for Pharma Manufacturing Newsletters
Get the latest news and updates